Eikon Therapeutics Inc (EIKN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.86-0.91%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · EIKN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
EIKN — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purpo…
Why it matters: More cash burn could mean financial trouble. Watching cash flow is important for staying in business.
Worry ifCash burn remains stable or decreases compared to previous quarters.
Less concerning ifCash burn is rising a lot beyond current levels.
Why it matters: A drop below this threshold could signal financial strain. It may raise concerns about funding future operations.
Worry ifCash reserves remain stable or increase from $531.2 million as of Q2 2026.
Less concerning ifCash reserves drop below $500 million. This shows faster cash spending.
Why it matters: Stable leaders are important for Eikon's recovery. More changes may mean bigger problems.
Worry ifLook for news about more executive changes or resignations in the next quarter.
Less concerning ifNo new executive changes will be announced in the next quarter.
Why it matters: Updates on EIK1003 will show how Eikon's cancer treatments are progressing. Good news could mean strong future growth.
Supportive ifThe EIK1003 trial shows positive early results. Patients are seeing better outcomes.
Worry ifEIK1003 trial reports delays or negative interim results.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$394 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $953 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,859 loss on $10,000 · 48.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The upcoming earnings report is crucial after two recent earnings misses. Investors will look for signs of recovery.
Watch forQ2 earnings report shows revenue growth above 5% year over year.
Also watch forQ2 earnings report shows revenue growth below 0% year over year.
Why it matters: The healthcare sector is slowing. Signs of growth could indicate a better environment for Eikon.
Supportive ifHealthcare sector revenue growth speeds up to about 10% year over year.
Worry ifHealthcare sector revenue growth slows down to below 5% year over year.
Why it matters: Earnings results will show if the company can manage losses amid increased R&D spending.
Worry ifNet loss is less than $83 million. This shows better cost management.
Less concerning ifNet loss is greater than $83 million. This shows worse financial health.
Why it matters: Early data on these PARP inhibitors may show their use in treating different cancers. Good results may increase the pipeline's value.
Supportive ifEIK1003 is safe and works well for advanced solid tumors.
Worry ifEIK1003 and EIK1004 data reveal safety issues or lack of efficacy.
Why it matters: Changes in leadership can change company plans and rules. This can affect trust and future goals.
Watch forNew board members or changes in leadership are announced.
Also watch forNo new news about board changes or stronger leadership.
Why it matters: This data will show how well EIK1001 works in treating NSCLC and melanoma. Positive results could boost confidence in the oncology pipeline.
Supportive ifEIK1001 Phase 2 data readout shows overall response rate above 60% in NSCLC cohort.
Worry ifEIK1001 Phase 2 data readout shows overall response rate below 40% in NSCLC cohort.
Why it matters: The results will show if EIK1001 works for advanced melanoma. Good results may lead to more work.
Supportive ifThe Data Monitoring Committee says to keep going with the TeLuRide-006 trial.
Worry ifThe committee suggests halting the trial due to safety or efficacy concerns.
Why it matters: More departures may show leadership problems. This can affect plans and investor trust.
Worry ifNo leaders are expected to leave in the next quarter.
Less concerning ifIf another leader leaves or is replaced, it may mean there are problems.
Why it matters: Cash updates will show if Eikon can fund operations through 2027 as planned.
Supportive ifCash position is above $596 million. This confirms funding into the second half of 2027.
Worry ifCash position falls below $596 million. This raises concerns about funding.
Why it matters: This data could confirm the effectiveness of EIK1001 in treating NSCLC. Positive results may boost investor confidence.
Supportive ifEIK1001 shows strong anti-tumor effects. The average response lasts over 11 months in NSCLC patients.
Worry ifEIK1001 data does not show strong clinical activity. There are no safety concerns.